PET重建方法是否影响淋巴瘤患者的Deauville评分
研究纳入126例弥漫大B细胞淋巴瘤患者,比较未滤波PSF重建与经6 mm滤波符合EANM/EARL协调化要求的PSF重建(PSFEARL)对Deauville评分及风险分层的影响。中期PET中两种重建的应答者/非应答者分类为60/40例对63/37例,治疗结束PET为69/26例对72/23例,一致性κ分别为0.82和0.89。无论采用何种重建,Kaplan-Meier分析显示应答者与非应答者的无进展生存和总生存差异均有统计学意义,结论为Deauville评分及风险分层不受重建方法影响。
要点
- 中期PET用PSF与PSFEARL分类应答者/非应答者为60/40例对63/37例,重大不一致5.0%。
- 治疗结束PET用PSF与PSFEARL分类应答者/非应答者为69/26例对72/23例,重大不一致3.2%。
- 两种重建的Deauville评分一致性κ在中期PET为0.82、治疗结束PET为0.89。
核心结论
- Deauville评分及弥漫大B细胞淋巴瘤患者风险分层不受PET重建方法选择的影响。
- 作者认为使用PSF在常规临床流程或多中心试验中不构成问题。
- 作者指出这些发现需在基于早期中期PET的升阶与降阶流程中进一步确认。
研究设计与样本
- 回顾性分析126例弥漫大B细胞淋巴瘤患者(56例女性、70例男性;中位年龄65岁,范围20-88岁)。
- PET数据采用未滤波PSF法重建,另对PSF图像施加6 mm滤波以满足EANM/EARL协调化要求(PSFEARL)。
- 分析100例中期PET和95例治疗结束PET研究;通过自动感兴趣体积测定肝脏和主动脉SUVmax,并与残留肿块最高18F-FDG摄取SUVmax比较。
- 中期PET和治療結束PET的中位随访时间分别为28.4个月和27.4个月。
主要发现
- 中期PET用PSF与PSFEARL分类应答者/非应答者分别为60/40例对63/37例,发生5例重大不一致(5.0%,即从应答者变为非应答者)。
- 治疗结束PET用PSF与PSFEARL分类应答者/非应答者分别为69/26例对72/23例,发生3例重大不一致(3.2%)。
- PSF与PSFEARL的Deauville评分一致性(Cohen未加权κ)在中期PET为0.82(95%CI 0.73-0.91),在治疗结束PET为0.89(95%CI 0.81-0.96)。
- Kaplan-Meier分析显示,无论中期PET和治疗结束PET采用何种重建,应答者与非应答者的无进展生存和总生存差异均有统计学意义。
局限性
- 作者指出这些发现需在基于早期中期PET的升阶与降阶流程中进一步确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
When evaluating 18F-FDG PET images with the Deauville score (DS), the quantification of tumor and reference organs limits the problem of optical misinterpretation. Compared with conventional reconstruction algorithms, point-spread function (PSF) modeling increases SUVs significantly in tumors but only moderately in the liver, which could affect the DS. We investigated whether the choice of the reconstruction algorithm affects the DS and whether discordance affects the capability of 18F-FDG PET to stratify lymphoma patients. Methods: Overall, 126 patients with diffuse large B-cell lymphoma were included (56 female and 70 male; median age, 65 y; range, 20-88 y). PET data were reconstructed with the unfiltered PSF method. Additionally, a 6-mm filter was applied to PSF images to meet the requirements of the EANM Research Ltd. (EARL) harmonization program from the European Association of Nuclear Medicine (EANM) (PSFEARL). One hundred interim PET (i-PET) and 95 end-of-treatment PET (EoT-PET) studies were analyzed. SUVmax in the liver and aorta was determined using automatic volumes of interest and compared with SUVmax in the residual mass with the highest 18F-FDG uptake. Results: For i-PET, using PSF and PSFEARL, we classified patients as responders and nonresponders in 60 and 40 cases versus 63 and 37 cases, respectively. Five cases of major discordance (5.0%) occurred (i.e., changes from responder to nonresponder). For Eot-PET, patients were classified using PSF and PSFEARL as responders and nonresponders in 69 and 26 cases versus 72 and 23 cases, respectively. Three cases of major discordance (3.2%) occurred. Concordance (Cohen unweighted κ) between the PSF and the PSFEARL DS was 0.82 (95% confidence interval, 0.73-0.91) for i-PET and 0.89 (95% confidence interval, 0.81-0.96) for EoT-PET. The median follow-up periods were 28.4 and 27.4 mo for i-PET and EoT-PET, respectively. Kaplan-Meier analysis showed statistically significant differences in progression-free survival and overall survival among responders and nonresponders no matter which reconstruction was used for i-PET and EoT-PET. Conclusion: Neither DS nor risk stratification of diffuse large B-cell lymphoma patients is affected by the choice of PET reconstruction. Specifically, the use of PSF is not an issue in routine clinical processes or in multicenter trials. These findings have to be confirmed in escalation and deescalation procedures based on early i-PET.
引用
- Enilorac B, Lasnon C, Nganoa C, et al. Does PET Reconstruction Method Affect Deauville Score in Lymphoma Patients? J Nucl Med. 2017. PMID: 29242403. doi:10.2967/jnumed.117.202721
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。